MUC16 and cancer: However, among patients receiving ICI therapy who had cancers other than NSCLC, we found no significant difference in OS (HR, 0.88; 95% CI, 0.72-1.07; P = .24) or PFS (HR, 1.08; 95% CI, 0.80-1.46; P = .60) between MUC16 variant and wild-type tumors.